Loading
A phase 2 trial of Pembrolizumab, Favezelimab in colorectal cancer, run by Merck Sharp & Dohme LLC, active and no longer recruiting.
Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008). is a phase 2 interventional study registered as NCT04895722 by Merck Sharp & Dohme LLC, with 302 participants enrolled, started 2021-06-25 and due to reach its primary completion in 2025-05-21. Interventions recorded: Pembrolizumab, Pembrolizumab/Quavonlimab, Pembrolizumab/Favezelimab, Pembrolizumab/Vibostolimab, MK-4830. Conditions listed: Colorectal Cancer. Results were posted on ClinicalTrials.gov in 2026; the figures recorded here are the registry's, not a publication's.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
302 enrolled.
95% CI 32.1 to 58.4; Figures from the ClinicalTrials.gov results section (first posted 2026-06-08), not from a publication · 95% CI 18.5 to 42.6 · 95% CI 30.1 to 62.8 · 95% CI 40.8 to 84.6 · 95% CI 22.7 to 54.2 · 95% CI 32.9 to 64.9 · 95% CI 26.3 to 57.9
SourceNA = Median and upper limit not reached at time of data cut-off due to insufficient number of participants with an event.; Figures from the ClinicalTrials.gov results section (first posted 2026-06-08), not from a publication · 95% CI 14.4 to NA · NA = Median, upper limit, and lower limit not reached at time of data cut-off due to insufficient number of participants with an event. · NA = Median and upper limit not reached at time of data cut-off due to insufficient number of participants with an event. · NA = Median and upper limit not reached at time of data cut-off due to insufficient number of participants with an event. · NA = Median, upper limit, and lower limit not reached at time of data cut-off due to insufficient number of participants with an event. · NA = Median and upper limit not reached at time of data cut-off due to insufficient number of participants with an event.
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)primary | Cohort A - Pembrolizumab/Quavonlimab | 60 | 45% | - | - | link |
| Cohort A - Pembrolizumab | 61 | 29.5% | ||||
| Cohort B - Pembrolizumab/Quavonlimab | 39 | 46.2% | ||||
| Cohort B - Pembrolizumab Plus MK-4830 | 20 | 65% | ||||
| Cohort B - Pembrolizumab/Favezelimab | 40 | 37.5% | ||||
| Cohort B - Pembrolizumab/Vibostolimab | 41 | 48.8% | ||||
| Cohort B - Pembrolizumab | 41 | 41.5% | ||||
| Overall Survival (OS) | Cohort A - Pembrolizumab/Quavonlimab | 60 | NA = Median and upper limit not reached at time of data cut-off due to insufficient number of participants with an event.; Figures from the ClinicalTrials.gov results section (first posted 2026-06-08), not from a publication | - | - | link |
| Cohort A - Pembrolizumab | 61 | 37.1 months | ||||
| Cohort B - Pembrolizumab/Quavonlimab | 39 | NA = Median, upper limit, and lower limit not reached at time of data cut-off due to insufficient number of participants with an event. | ||||
| Cohort B - Pembrolizumab Plus MK-4830 | 20 | NA = Median and upper limit not reached at time of data cut-off due to insufficient number of participants with an event. | ||||
| Cohort B - Pembrolizumab/Favezelimab | 40 | NA = Median and upper limit not reached at time of data cut-off due to insufficient number of participants with an event. | ||||
| Cohort B - Pembrolizumab/Vibostolimab | 41 | NA = Median, upper limit, and lower limit not reached at time of data cut-off due to insufficient number of participants with an event. | ||||
| Cohort B - Pembrolizumab | 41 | NA = Median and upper limit not reached at time of data cut-off due to insufficient number of participants with an event. |
Shares Favezelimab, Merck & Co. (MSD), Pembrolizumab, Immune checkpoint inhibitors.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Merck & Co. (MSD), Pembrolizumab, Colorectal cancer.
Shares Favezelimab, Merck & Co. (MSD), Pembrolizumab, Immune checkpoint inhibitors.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Pembrolizumab, Colorectal cancer, Immune checkpoint inhibitors.
Shares Favezelimab, Merck & Co. (MSD), Immune checkpoint inhibitors.
Shares Favezelimab, Merck & Co. (MSD), Pembrolizumab.
Shares Favezelimab, Merck & Co. (MSD), Pembrolizumab.
Shares Mismatch-repair deficient (MSI-high) colorectal cancer, Colorectal cancer, Immune checkpoint inhibitors.